Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust), George Seed(Institute of Cancer Research), Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Jacob Tanguay(Velindre Cancer Centre), Angus Robinson(Royal Sussex County Hospital), Bora Gürel(Institute of Cancer Research), Ursula McGovern(University College Hospital), Rita Pereira(Institute of Cancer Research), Alison Birtle(Royal Lancaster Infirmary), Matthew Clarke(Institute of Cancer Research), Mateus Crespo(Institute of Cancer Research), Berni Ebbs(Institute of Cancer Research), Robert J. Jones(Beatson West of Scotland Cancer Centre), Andra Curcean(Royal Marsden NHS Foundation Trust), Nina Tunariu(Leicester Royal Infirmary), Emma Hall(Institute of Cancer Research), Gemma Fowler, Susana Miranda(Royal Marsden NHS Foundation Trust), Shahneen Sandhu(The University of Melbourne), Omi Parikh(Royal Blackburn Teaching Hospital), Ruth Riisnaes(Institute of Cancer Research), Penny Flohr(Royal Marsden NHS Foundation Trust), Christy Ralph(University of Leeds), Peter Chatfield(Institute of Cancer Research), Núria Porta, Ana Ferreira(Institute of Cancer Research), Tony Elliott(The Christie Hospital), Aude Espinasse(Institute of Cancer Research), Daniel Nava Rodrigues(Institute of Cancer Research), Simon J. Crabb(University of Southampton), Isabel Syndikus(San Antonio College), Suzanne Carreira(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Robert W. Chandler(Oldham Council), Mohini Varughese(Musgrove Park Hospital), Duncan B. McLaren(NHS Lothian), Suneil Jain(Queen's University Belfast), Cláudia Bertan(Institute of Cancer Research)
Cited by 643
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k